|Articles|September 29, 2015

ACRES, Clinical Trials Ontario Form Partnership

See this news from Pharmaceutical Executive on the latest out of ACRES.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

© JHVEPhoto - © JHVEPhoto - stock.adobe.com

FDA Finalizes Three Guidances to Broaden Cancer Clinical Trial Eligibility

ByAndy Studna, Senior Editor

July 29th 2026

Beyond Compliance: YPrime's Paulo Limgenco on Moving ESG From Reporting to Real Business Value

ByOtis Johnson, PhD, MPA,Paulo Limgenco

July 29th 2026

What Needs to Be True for the FDA's Real-Time Pilot Model to Work Beyond Big Pharma

ByRaviv Pryluk, PhD,Andy Studna, Senior Editor

July 29th 2026

ACT Brief: Data Pipeline Standardization for Real-Time Analysis, Sponsor Accountability Beyond Contracts, and Autoimmune Pipeline Expansion

ByAndy Studna, Senior Editor

July 29th 2026

The Handoff Illusion: Why Clean Transitions in Clinical Development Are a Myth

ByElizabeth Walsh, PMP, ACRP-CP

July 28th 2026

ACRES, Clinical Trials Ontario Form Partnership

Related Content

FDA Finalizes Three Guidances to Broaden Cancer Clinical Trial Eligibility

Beyond Compliance: YPrime's Paulo Limgenco on Moving ESG From Reporting to Real Business Value

What Needs to Be True for the FDA's Real-Time Pilot Model to Work Beyond Big Pharma

ACT Brief: Data Pipeline Standardization for Real-Time Analysis, Sponsor Accountability Beyond Contracts, and Autoimmune Pipeline Expansion

The Handoff Illusion: Why Clean Transitions in Clinical Development Are a Myth

Trending on Applied Clinical Trials Online

The Handoff Illusion: Why Clean Transitions in Clinical Development Are a Myth

ACT Brief: Data Readiness Gap in Continuous Monitoring, Workflow-Centric AI Deployment, and First-in-Class ADHD Mechanism

ACT Brief: Inspection Readiness Throughout Lifecycle, AI Churn and Operational Discipline, and Global Trial Stakeholder Alignment

Workflow in the Age of AI

Beyond Compliance: YPrime's Paulo Limgenco on Moving ESG From Reporting to Real Business Value